선택한 단어 수는 입니다.
최소 단어 이상 선택하여야 합니다.
최소 단어 이상 선택하여야 합니다.
선택한 단어 수는 30입니다.
최대 10 단어까지만 선택 가능합니다.
최대 10 단어까지만 선택 가능합니다.
제안 방법
- Another study assessed the effect of topiramate on binging and purging behavior, body weight, and the health-related quality of life (HRQOL) in patients with BN.9) The researchers conducted a 10-week randomized, double-blind, placebo-controlled study. One hundred two women aged 18 years or older who had been suffering from DSM-IV BN for at least 12 months were included in the study.
- Topiramate was titrated from an initial dose of 25 mg/ day up to 600 mg/day. During the extension trial, patients were evaluated every 4 weeks. A 1-sample paired t-test was used to evaluate the weekly frequency of bingeeating episodes before each clinic visit.
- 071), although that did not meet statistical significance. The limitations of the study were the small sample size and short treatment period. According to the results of the study, topiramate may be potential for the treatment of BN.
- 001). The study has several limitations, i.e., an uncontrolled, open-label trial with a small sample size and high attrition rate. Despite these limitations, the study suggests that topiramate may be effective for patients with BED and obesity.
- No serious side effects were reported during the study. The study suggests that topiramate is a safe and effective agent for improving the binging/purging behavior and the HRQOL in patients with BN, but there are limitations in the study. The sample size was relatively small and only women were included in the study.
- 1) conducted a 14-week, single-center, randomized, double-blind, placebo-controlled study in 61 patients with DSM-IV (Diagnostic and Statistical Manual of Mental Disorders; Version IV, published in 1994) BED and obesity (BMI>30 kg/m2). The study was followed by an open-label, 42-week extension study for patients who completed the placebo-controlled trial. Topiramate was titrated from an initial dose of 25 mg/ day up to 600 mg/day.
대상 데이터
- 9) The researchers conducted a 10-week randomized, double-blind, placebo-controlled study. One hundred two women aged 18 years or older who had been suffering from DSM-IV BN for at least 12 months were included in the study. Sixty patients were randomly assigned to receive topiramate (topiramate group [TG]; n=30) or a placebo (control group [CG]; n=30).
- In 3 out of the 5 cases in the series, topiramate almost completely eliminated binging and purging behavior. One of the patients discussed was a 36-year-old woman with BN and depression. She was prescribed citalopram 120 mg, gabapentin 800 mg, olanzapine 30 mg, lamotrigine 150 mg (all given at bedtime), and dextroamphetamine, 10 mg twice daily.
- A 1-sample paired t-test was used to evaluate the weekly frequency of bingeeating episodes before each clinic visit. Thirty one patients entered the open-label extension trial. Fifteen patients received topiramate during the double-blind study and 16 patients received placebo.
데이터처리
- During the extension trial, patients were evaluated every 4 weeks. A 1-sample paired t-test was used to evaluate the weekly frequency of bingeeating episodes before each clinic visit. Thirty one patients entered the open-label extension trial.
이론/모형
- Sixty patients were randomly assigned to receive topiramate (topiramate group [TG]; n=30) or a placebo (control group [CG]; n=30). The nonparametric Mann-Whitney U test was performed to evaluate the primary outcome measures of changes in the frequency of binging/purging, in body weight, and in the HRQOL by using the SF-36 Health Survey (SF- 36) scales. The SF-36 consists of a questionnaire with 36 items that are categorized according to several subject areas.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.